Great Bay Bio Partners with Cytiva to Advance Drug Development
GBB
AI Biomedical R&D Company
Cytiva
Cell and Gene Therapy CDMO
On August 2 (next Friday), Cytiva will host an industry conference at Shenzhen Bay.Invite colleagues from all sectors of the industry to gather together,Dr. Liang Chen, CEO and Co-founder of Great Bay Bio, attended as a special guest speaker to discuss cutting-edge technologies and application experiences, facilitating the future development of drug research and development.
Great Bay Bio focuses on the upstream end of drug discovery and CMC development, while Cytiva has rich experience in the downstream end such as purification, effectively addressing the long-standing pain points of "high cost, high risk, and long cycle" in drug development.
▲Scan the QR code to register for the conference
Dr. Liang Chen, CEO and Co-founder of Great Bay Bio, will deliver a speech titled "AI-Powered Drug Development," illustrating how Great Bay Bio applies its AI technology platform to drive innovation in biopharmaceuticals.Covering the entire process from molecular design to the CMC stage, including antibody sequence generation, high-activity protein sequence generation, targeted integration cell line screening, one-stop medium optimization, etc., to help customers develop products faster and better.
▲GBB CEO and Co-founder Dr. Chen Liang will give a speech
Cytiva is committed to providing users with high-quality products and services. Its ÄKTA chromatography system is synonymous with chromatography technology, facilitating the successful launch of hundreds of drugs (proteins, peptides, nucleic acids, etc.). During the conference, Cytiva will explore cutting-edge chromatography technologies and host a grand promotional event to help users address challenges in downstream chromatography development.
For more conference details, please click "Read Original" at the lower left corner.
END
Tel: 400 079 8808
18926497707 (Same number on WeChat)
Email: BD@greatbay-bio.com
